about
Drug delivery interfaces: A way to optimize inhalation therapy in spontaneously breathing childrenRandomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic chargeCanadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.Lung deposition of aerosol--a comparison of different spacersEffect of plastic spacer handling on salbutamol lung deposition in asthmatic children.Age dependent systemic exposure to inhaled salbutamol.Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children.Reducing electrostatic charge on spacer devices and bronchodilator response.In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhalerAerosol therapy in children: challenges and solutions.Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants.Delivery of inhaled medication to children.Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizerEarly bioavailability of inhaled salbutamol reflects lung dose in children.Drug delivery from inhaler devices.Delivery of salbutamol pressurized metered-dose inhaler administered via small-volume spacer devices in intubated, spontaneously breathing rabbits.Bronchodilation with mometasone furoate/formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma.A review of the in vitro and in vivo valved holding chamber (VHC) literature with a focus on the AeroChamber Plus Flow-Vu Anti-static VHC.Automatic actuation of a dry powder inhaler into a nonelectrostatic spacer.Impact of constant and breath-synchronized nebulization on inhaled mass of nebulized budesonide in infants and children.Inhalation treatment: errors in application and difficulties in acceptance of the devices are frequent in wheezy infants and young children.Spacer devices for inhaled therapy: why use them, and how?
P2860
Q28074565-E3CAE3F9-5711-4424-82FC-890A33C6AE1FQ28346185-E40450BF-F76F-439E-BBE6-8680A0EBB6D6Q33976334-979E720C-B8C1-4FB5-9EF6-6834F052697FQ35266692-C68DD8E1-0AD7-4B53-BB4C-92BCD3A640D1Q35804135-F01B7ED9-7954-4C87-938D-854FC8EFACADQ36024565-EB9CB545-6439-4E4F-B031-BFD35671C507Q36053350-74F99B35-BE57-4DE9-8B2C-092E16C24D18Q36055281-EB366294-15F7-4CBC-8B63-E7C8460C300EQ37161509-DB3113CC-8E35-4F8F-BE0C-814FFC9D6B58Q38162255-F347264C-B60A-4D97-A7D2-CFC16D557C8AQ41207776-3B0A7EDB-7E20-4C45-B228-ED6A7282CEA1Q41680896-DE3715FD-1CB0-4C4F-9FB8-03997FD215BCQ41826826-002EC618-73D6-4B09-9778-2AA537F45DEDQ43112628-B86ED028-304D-4B7E-9672-72117AA6CFE2Q43189977-B21BCEAA-E526-47AF-9901-A754BDAD8AAAQ43717152-98D98CC0-D673-400D-A050-A9A3044AF3ABQ44076747-29CDA3C9-445C-4A09-90D7-A0F60C8ADEF0Q49600518-CA8AD9E6-3F13-46CA-9B91-F4B3E9B84B26Q53583076-E40F5743-80E7-4FA5-83F8-EEE18F222A70Q54441825-5A9A78E4-5756-4F4B-A819-E07D3514FC20Q54718751-CEDD529B-336E-4816-9F85-9B2A3546AF9AQ55241851-A9289B2A-BD48-46DE-923B-5994B4D8595A
P2860
description
1995 nî lūn-bûn
@nan
1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
A non-electrostatic spacer for aerosol delivery
@ast
A non-electrostatic spacer for aerosol delivery
@en
A non-electrostatic spacer for aerosol delivery
@nl
type
label
A non-electrostatic spacer for aerosol delivery
@ast
A non-electrostatic spacer for aerosol delivery
@en
A non-electrostatic spacer for aerosol delivery
@nl
prefLabel
A non-electrostatic spacer for aerosol delivery
@ast
A non-electrostatic spacer for aerosol delivery
@en
A non-electrostatic spacer for aerosol delivery
@nl
P2860
P356
P1476
A non-electrostatic spacer for aerosol delivery
@en
P2860
P304
P356
10.1136/ADC.73.3.226
P407
P577
1995-09-01T00:00:00Z